Imaging tumour response: beyond RECIST by unknown
ORAL PRESENTATION Open Access
Imaging tumour response: beyond RECIST
Dow-Mu Koh
From International Cancer Imaging Society (ICIS) 14th Annual Teaching Course
Heidelberg, Germany. 9-11 October 2014
One of the most widely employed quantitative measure-
ments for assessing tumour response to treatment is the
tumour diameter (RECIST criteria), usually determined on
cross-sectional CT or MRI. This simple measurement is
relatively reproducible and reduction in the maximum
tumour diameter by 30% or more following therapy is
taken as a sign of effective treatment. However, new
targeted therapies may be effective without significantly
reducing tumour size and other quantitative response
criteria are being evaluated.
Some of the response criteria being evaluated combine
tumour diameter measurement with other quantitative
assessment (e.g. CT density). These have been applied
towards the evaluation of gastrointestinal stromal tumours
(CHOI criteria) and renal cell carcinoma (modified or
revised CHOI criteria) undergoing multi-kinase inhibitor
treatment; and hepatocellular carcinoma (modified
RECIST criteria) treated with novel therapeutics or
chemoembolization. In these clinical settings, the applica-
tions of such criteria for tumour response assessment have
shown better correlation with clinical outcome compared
with conventional RECIST criteria. When immunotherapy
is administered, conventional RECIST criteria may erro-
neously ascribe the appearance of new lesions to disease
progression; whereas this phenomenon is given due
consideration within the immune-related response criteria
(irRC).
As quantitative imaging becomes increasingly important
in oncology, quantitative indices are being applied and
developed in CT, MRI and PET imaging for tumour
response assessment. Using perfusion CT technique, the
change in CT attenuation value with time resulting from
the passage of contrast through tissue can be used to
calculate quantitative vascular parameters such as perme-
ability surface area product (PS), blood flow (F) and mean
transit time (MTT). Using dual energy CT, it is possible to
obtain quantitative iodine contrast distribution in soft
tissue.
MRI is a powerful multiplex imaging technique
because depending on how the scans are performed, it
can yield different quantitative information. Two of the
most widely employed quantitative techniques for
tumour assessment are dynamic contrast enhanced MRI
(DCE-MRI) and diffusion-weighted MRI (DW-MRI).
The former has been used in early phase trials for the
assessment of antivascular/ antiangiogenic therapies.
The latter has shown potential as an early response
biomarker to a range of effective treatments including
chemotherapy, radiotherapy, chemoemobolization treat-
ment and novel therapeutics. Other clinical MR techni-
ques include intrinsic susceptible contrast imaging and
magnetic resonance spectroscopy (MRS). However,
these have currently limited value for assessing tumour
response to treatment.
PET imaging using 18FDG tracer enables the semi-
quantitative standardised uptake value (SUV) to be
derived. PET imaging is increasing utilized for tumour
response assessment, and forms the basis of standard
criteria for assessment of tumour response in lymphoma.
By performing dynamic imaging, it is also possible to
calculate the quantitative tracer uptake in tissues. The
strength of PET imaging is the range of radiolabelled
tracers that are now available clinically to probe a range of
tissue properties.
In early phase trials, quantitative imaging other than
tumour size measurements using CT, MRI or PET can
provide mechanistic information about drug action, and
also therapeutic effects on specific aspects of tumour biol-
ogy (e.g. vascularity, cellularity). By using multimodality
imaging, there is also an opportunity to corroborate
imaging measurements made using one technique with
another. However, quantitative techniques require a
process of quality control and quality assurance; as well as
knowledge of their measurement reproducibility so that
they can be applied with confidence in clinical practice.
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